New heart test could spare transplant patients from risky biopsies

NCT ID NCT06656065

Recruiting now Knowledge-focused Sponsor: Hospital Miguel Servet Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new way to monitor heart transplant patients for rejection using a simple catheter-based measurement called IMR. The goal is to see if this test can identify high-risk patients and reduce the need for invasive biopsies. Researchers will follow 100 heart transplant recipients for one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a safer, less invasive way to monitor heart transplant patients for rejection, potentially reducing the need for risky biopsies.
What could go wrong: This is an observational study, not a treatment trial. It may not change clinical practice if the IMR measurement does not reliably predict rejection or outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART TRANSPLANT REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART TRANSPLANT REJECTION MICROVASCULAR RESISTANCE

Contacts and locations

Locations

Hospital Miguel Servet
RECRUITING

Zaragoza, Zaragoza, 50009, Spain
Hospital Universitario de Bellvitge
ACTIVE_NOT_RECRUITING

L'Hospitalet de Llobregat, Barcelona, 08907, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.